SCHEMBL267110

SCHEMBL267110

CCN(CCO)Cc1ccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2cccc(C)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
F10 P00742 13/20 0.51
SLC34A2 O95436 1/20 0.47
SLC34A1 Q06495 1/20 0.47
SLC34A3 Q8N130 1/20 0.47
SLC20A1 Q8WUM9 1/20 0.47
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 4/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
RECQL P46063 1/20 0.44
KLKB1 P03952 4/20 0.42
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267111 1.00 F10 (0.51) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL270396 0.93 SLC34A2 (0.54) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL270395 0.93 SLC34A2 (0.54) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL266013 0.93 F10 (0.51) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL266012 0.93 F10 (0.51) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL266130 0.91 SLC34A2 (0.57) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL266129 0.91 SLC34A2 (0.57) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL267554 0.91 F10 (0.53) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL267553 0.91 F10 (0.53) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL269130 0.90 F10 (0.58) F10SLC34A2SLC34A1SLC34A3SLC20A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 F10 188/4885SLC34A2 6/4885SLC34A1 4/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 F10 338/4885SLC34A2 2/4885SLC34A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.